Exact Sciences Corporation (EXAS)

Market Cap	10.19B
Revenue (ttm)	2.94B
Net Income (ttm)	-1.01B
Shares Out	189.32M
EPS (ttm)	-5.40
PE Ratio	n/a
Forward PE	75.36
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,127,254
Open	51.49
Previous Close	51.41
Day's Range	51.18 - 54.36
52-Week Range	38.81 - 72.83
Beta	1.05
Analysts	Strong Buy
Price Target	66.43 (+23.45%)
Earnings Date	Nov 4, 2025

About EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Ri...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1995
• Employees: 7,000
• Stock Exchange: NASDAQ
• Ticker Symbol: EXAS
• Website: https://www.exactsciences.com

Financial Performance

In 2024, Exact Sciences's revenue was $2.76 billion, an increase of 10.37% compared to the previous year's $2.50 billion. Losses were -$1.03 billion, 404.0% more than in 2023.

Analyst Summary

According to 22 analysts, the average rating for EXAS stock is "Strong Buy." The 12-month stock price target is $66.43, which is an increase of 23.45% from the latest price.

Price Target

$66.43

(23.45% upside)

Analyst Consensus: Strong Buy